肝动脉灌注化疗及其综合治疗方案对中晚期肝细胞癌患者的临床疗效及预后因素分析  

Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors

作　　者：戴文聪[1] 臧梦雅 袁国盛 李祺[1] 李榕[1] 李文利 董书语 陈锦章[1] DAI Wencong;ZANG Mengya;YUAN Guosheng;LI Qi;LI Rong;LI Wenli;DONG Shuyu;CHEN Jinzhang(Department of Infectious Diseases and Hepatology Unit,Nanfang Hospital,Southern Medical University,State Key Laboratory of Organ Failure Research,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Guangdong Provincial Institute of Liver Diseases,Guangzhou 510515,China;The First Clinical Medical College,Southern Medical University,Guangzhou 510515,China)

机构地区：[1]南方医科大学南方医院肝病中心暨感染内科,器官衰竭国家重点实验室,广东省病毒性肝炎研究重点实验室,广东省肝脏疾病研究所,广州510515 [2]南方医科大学第一临床医学院,广州510515

出　　处：《临床肝胆病杂志》2023年第7期1592-1599,共8页Journal of Clinical Hepatology

基　　金：广东省自然科学基金(2022A1515010526);南方医科大学南方医院院长基金(2018C006)。

摘　　要：目的 本研究旨在观察FOLFOX方案持续肝动脉灌注化疗(HAIC)及其综合治疗方案对中晚期肝细胞癌患者的临床疗效并分析影响预后的因素。方法 回顾性收集南方医科大学南方医院2018年9月-2021年11月行FOLFOX方案持续HAIC的66例中晚期肝细胞癌患者临床资料。观察治疗后患者的客观缓解率、疾病控制率、中位无疾病进展生存时间(mPFS)和中位生存时间(mOS)并记录治疗相关不良反应。针对伴有门静脉癌栓的患者,评价治疗对门静脉癌栓的疗效。采用Kaplan-Meier法进行生存分析。采用Cox回归分析影响预后的因素。结果 按照RECIST1.1标准,FOLFOX-HAIC及其综合治疗方案治疗66例中晚期肝细胞癌患者的客观缓解率和疾病控制率分别为33.3%(22/66)、86.4%(57/66),mPFS和mOS分别为8.2个月和22.1个月。其中39例合并门静脉癌栓的肝癌患者中完全缓解2例,部分缓解8例,稳定24例,进展5例。客观缓解率为25.6%(10/39),疾病控制率为87.2%(34/39)。不良反应主要为消化道反应16.7%(11/66)、发热12.1%(8/66)、肝区疼痛10.6%(7/66)、骨髓抑制3.0%(2/66)和造影剂过敏3.0%(2/66)。无Ⅳ级以上的毒副反应。无并发症导致的死亡。Cox分析显示肝外转移(HR=2.668,95%CI:1.357~5.245)和凝血酶原时间(HR=1.282,95%CI:1.080~1.630)是影响患者PFS的独立危险因素(P值均<0.05), AST水平(HR=1.008,95%CI:1.002~1.013)和凝血酶原时间(HR=1.303,95%CI:1.046~1.630)是影响患者OS的独立危险因素(P值均<0.05)。结论 FOLFOX-HAIC及其综合治疗方案治疗中晚期肝细胞癌有一定的疗效,不良反应可控。Objective To investigate the efficacy of continuous hepatic arterial infusion chemotherapy(HAIC)with the FOLFOX regimen and its multimodality therapeutic regimen in the treatment of patients with advanced hepatocellular carcinoma,as well as the influencing factors for prognosis.Methods A retrospective analysis was performed for the clinical data of 66 patients with advanced hepatocellular carcinoma who received continuous HAIC with FOLFOX regimen in Nanfang Hospital,Southern Medical University,from September 2018 to November 2021.The patients were observed in terms of objective response rate(ORR),disease control rate(DCR),median progression-free survival(mPFS),and median overall survival(mOS)after treatment,and treatment-related adverse reactions were recorded.For the patients with portal vein tumor thrombus,the effect of the treatment on portal vein tumor thrombus was assessed.The Kaplan-Meier method was used for survival analysis,and the Cox regression analysis was used to investigate the influencing factors for prognosis.Results According to the RECIST1.1 criteria,FOLFOX-HAIC and its multimodality therapeutic regimen achieved an ORR of 33.3%(22/66)and a DCR of 86.4%(57/66)in the treatment of 66 patients with advanced hepatocellular carcinoma,with an mPFS time of 8.2 months and an mOS time of 22.1 months.Among the 39 patients with portal vein tumor thrombus,2 achieved complete remission,8 achieved partial remission,24 achieved stable disease,and 5 had disease progression,with an ORR of 25.6%(10/39)and a DCR of 87.2%(34/39).The main adverse reactions included gastrointestinal reactions(16.7%,11/66),pyrexia(12.1%,8/66),liver area pain(10.6%,7/66),bone marrow suppression(3.0%,2/66),and contrast agent allergy(3.0%,2/66),and there were no grade>Ⅳtoxic or side effects or deaths caused by such complications.The Cox regression analysis showed that extrahepatic metastasis(hazard ratio[HR]=2.668,95%confidence interval[CI]:1.357-5.245,P<0.05)and prothrombin time(PT)(HR=1.282,95%CI:1.080-1.630,P<0.05)were independent ris

关 键 词：癌 肝细胞 分子靶向治疗 预后 

分 类 号：R735.7[医药卫生—肿瘤]